๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Prognostic factors in multiple myeloma

โœ Scribed by Nehemiah C. Cherng; Nabih R. Asal; Elisa T. Lee; J. Philip Kuebler; Dilip Solanki

Book ID
102670821
Publisher
John Wiley and Sons
Year
1991
Tongue
English
Weight
682 KB
Volume
67
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Prognostic factors in multiple myeloma
Prognostic factors in multiple myeloma
โœ Raymond Alexanian; Stanley Balcerzak; John D. Bonnet; Edmund A. Gehan; Arthur Ha ๐Ÿ“‚ Article ๐Ÿ“… 1975 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 751 KB

Includes 17 patients with untyped light chains.

Prognostic factors in multiple myeloma:
Prognostic factors in multiple myeloma: role of ?2-microglobulin and thymidine kinase
โœ Diem, H. ;Fateh-Moghadam, A. ;Lamerz, R. ๐Ÿ“‚ Article ๐Ÿ“… 1993 ๐Ÿ› Springer-Verlag ๐ŸŒ English โš– 722 KB

Serum [32-microglobulin , serum thymidine kinase, and commonly used prognostic parameters were investigated for their prognostic value in a well-defined group of patients with multiple myeloma (n = 207). Multivariate analysis showed hemoglobin to be the parameter of strongest prognostic value. Only

O23 Proliferation and apoptosis in multi
O23 Proliferation and apoptosis in multiple myeloma prognostic factors or kinetic parameters?
โœ J. Minarik; V. Scudla; M. Ordeltova; J. Bacovsky; M. Zemanova; T. Pika ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 47 KB

note, in 19 patients, remission achieved by bortezomib-based therapy was consolidated by high-dose therapy followed by autologous stem cell transplantation. With a median follow-up time of 11 months (1 27 months), the median progression-free survival of our entire patient population is 13.8 month, w